Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | F10 | P00742 | 5/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 6/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL77494 | 0.82 | MAPK1 (0.47) | MAPK1F10HPGDTSHR | |
| SCHEMBL3151178 | 0.77 | MAPK1 (0.42) | MAPK1F10HPGDTSHR | |
| SCHEMBL78671 | 0.77 | HPGD (0.49) | MAPK1F10HPGDTSHR | |
| SCHEMBL4557626 | 0.76 | MAPK1 (0.44) | MAPK1F10HPGDTSHR | |
| SCHEMBL15731743 | 0.76 | F10 (0.48) | MAPK1F10HPGDTSHR | |
| SCHEMBL78765 | 0.76 | MAPK1 (0.43) | MAPK1F10HPGDTSHR | |
| SCHEMBL79316 | 0.76 | F10 (0.57) | MAPK1F10HPGDTSHR | |
| SCHEMBL4458638 | 0.74 | MAPK1 (0.44) | MAPK1F10HPGDTSHR | |
| SCHEMBL4278332 | 0.74 | MAPK1 (0.41) | MAPK1F10HPGDTSHR | |
| SCHEMBL77756 | 0.74 | MAPK1 (0.41) | MAPK1F10HPGDTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080200674-A1 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE IN THE FIELD OF BLOOD COAGULATION | BAYER HEALTHCARE AKTIENGESELLSCHAFT (DE) | 2008-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200674-A1 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE IN THE FIELD OF BLOOD COAGULATION | F2, F11, F13B | MAPK1 3637/4885F10 9/4885TRPV1 4858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.